Petros Pharmaceuticals, Inc. (PTPI): Nasdaq/NYSE listing notice — Petros gets additional Nasdaq delisting notice for Feb 2025 offering; completes 1-for-25 reverse split

Petros Pharmaceuticals, Inc.

Nasdaq notified Petros on April 28 of public interest concerns regarding its February 19, 2025 public offering as a new delisting basis under Rule 5810(d).
Company intends to address concerns before a Nasdaq Hearings Panel; delisting actions are stayed pending the hearing.
1-for-25 reverse stock split effective 4:05 pm ET April 30, 2025; split-adjusted trading began May 1, 2025, under same symbol PTPI.
No fractional shares issued; authorized shares remain 7 billion; proportionate adjustments made to options and equity plan.
New CUSIP number is 71678J308; the reverse split does not immediately affect trading.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Petros Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding other (rules 5810(c)(3)(A)(iii), 5810(d)).

Exchange: nasdaq
Notice: delisting notice
Rules: 5810(c)(3)(A)(iii), 5810(d)

Exact text from the filing

April 28, 2025, Nasdaq notified the Company (the “ Notice ”) it had public interest concerns regarding the Company’s public offering of securities that closed on February 19, 2025, which serves as an additional basis for delisting the Company’s securities pursuant to Nasdaq Listing Rule 5810(d). The Company intends to address these concerns before a Nasdaq Hearings Panel (the “ Panel ”). As a result of the Company’s hearing request pending appeal notice, all delisting actions have been stayed, pending a hearing before the Panel. The Notice has no immediate impact on the Company’s common stock

View on SEC.gov

88 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Petros Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-044240

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.